Overview

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Status:
Withdrawn

Trial end date:
2016-11-15

Target enrollment:

Participant gender:

Summary

This is a study to investigate the absorption, metabolism and excretion of [14C] labeled ASP8273 in subjects with solid tumors harboring EGFR mutations (per local testing). This study consists of two parts (A and B).

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Naquotinib